Abingdon Health

What Abingdon Health does

Abingdon Health plc is a UK-headquartered, AIM-listed contract development and manufacturing organization (CDMO) specialising in lateral flow diagnostic assays. Founded in 2008 in York, England, and now employing 251-500 staff across the UK and US, the company provides end-to-end lateral flow services — concept, assay development, scale-up, technical transfer, ISO 13485-certified manufacturing, regulatory submissions, and performance evaluation — to pharma, biotech and diagnostic companies that lack in-house lateral flow capability. Its core technology stack spans sandwich immunoassays, nucleic acid lateral flow amplification, multiplexed panels, fluorescent particle and quantum dot signal amplification, and digital reader/smartphone integration with EHR connectivity. Manufacturing capacity exceeds 100 million devices annually, delivered from a York, UK facility and a Madison, Wisconsin facility opened in April 2025.

Revenue is generated through four streams: (i) professional-services CDMO contracts, billed on multi-year quote-based terms; (ii) regulatory consultancy delivered through Compliance Solutions and IVDeology (acquired May and August 2024 for a combined ~£3.9 million); (iii) hardware product sales under consumer/professional brands including Pocket Diagnostic, Abingdon Simply Test, Salistick and PCRD; and (iv) analytical testing through Abingdon Analytical. Customer segments are verticalised — primary in pharma/biotech/diagnostics and animal health, with secondary exposure to plant health, environmental testing, food safety and pharmaceutical clinical trials. Go-to-market is enterprise field sales supplemented by industry events (ADLM, Next Generation Dx Summit) and active investor-relations engagement; the company cross-lists on AIM (ABDX) and OTCQB (ABDXF from April 2026).

Name

Abingdon Health

Legal name

Abingdon Health plc

Website

https://abingdonhealth.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics Contract Manufacturing

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industry

Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)

Keywords

• Lateral flow diagnostics
• Contract development manufacturing
• Rapid diagnostic testing
• IVD regulatory services
• Companion diagnostics

Headquarters

HQ city

York

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Full-service CDMO providing lateral flow assay development, scale-up, technical transfer, and commercial manufacturing for pharma, biotech and diagnostic companies. Revenue generated through project-based contracts and long-term manufacturing agreements.
2. Regulatory Services: Regulatory consultancy through Compliance Solutions and IVDeology subsidiaries, offering GAP analysis, technical file build, clinical trial design, stability studies, and approval submissions for IVD and medical device markets.
3. Lateral Flow Products: Sale of lateral flow products including rapid test brands (Pocket Diagnostic, Abingdon Simply Test) to consumers, retail, wholesale and distributors across multiple industries including healthcare, animal health and plant health.
4. Analytical Testing Services: Performance evaluation and analytical testing services through Abingdon Analytical for lateral flow and IVD assay regulatory approval data generation.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Abingdon Health is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end lateral flow diagnostic development, manufacturing, regulatory, and analytical testing services. The company serves pharma, biotech, and diagnostic companies from US (Madison, Wisconsin) and UK (York) ISO 13485 certified facilities, while also distributing consumer-facing rapid test brands including Pocket Diagnostic, Abingdon Simply Test, and Salistick through retail and wholesale channels.

Product overview

Abingdon Health is a Contract Development and Manufacturing Organization (CDMO) offering integrated lateral flow diagnostic development and manufacturing services. The portfolio comprises the core Lateral Flow CDMO Services platform supported by specialized modules including Development, Scale-Up & Technical Transfer, Manufacturing & Packaging, Regulatory Services (via Compliance Solutions and IVDeology), Companion Diagnostics Development, and Performance Evaluation Services (via Abingdon Analytical). The company also operates consumer-facing sub-brands including Abingdon Simply Test and Pocket Diagnostic for direct-to-market rapid test products. Subsidiaries IVDeology and Compliance Solutions provide regulatory consultancy services, while Abingdon Analytical offers analytical testing. Services span across multiple sectors including clinical diagnostics, animal health, plant health, defense, environment, pharmaceutical, and food testing. The company maintains dual manufacturing capabilities in York, UK and Madison, Wisconsin, USA.

Differentiator

Problem solved

Functional benefit

Brands

• PCRD: A range providing researchers with simplified approaches to testing their molecular lateral flow systems with an off-the-shelf lateral flow solution
• Salistick

Products and services

• Lateral Flow CDMO Services End-to-end lateral flow development, manufacturing and regulatory solutions from US and UK locations, providing integrated services from concept to commercialisation including development, scale-up, technical transfer, manufacturing, regulatory support, and performance evaluation.
• USA Lateral Flow CDMO Services US-based lateral flow assay development and manufacturing facility in Madison, Wisconsin offering CDMO services including development, scale-up, ISO 13485 certified manufacturing, and regulatory support for 510(k) submissions with tariff-free domestic production and FDA-ready quality systems.
• Lateral Flow CDMO Development Contract development services for lateral flow assays including design for manufacture, reagent assessment, materials evaluation, prototype development for Proof of Concept, and optimization through Design Freeze.
• Lateral Flow Scale-Up & Technical Transfer Transferring processes from bench to pilot/validation batches with QC methodology, supply chain support, formal SOPs and BOMs ready for Final Output Review.
• Lateral Flow Manufacturing & Packaging Flexible manufacturing solutions from tailored strip and card manufacturing including reagent preparation, spraying, lamination, to full kitting and assembly, foiling and QC processes to Final Batch Release.
• Regulatory Services In-house regulatory consultancy supporting GAP analysis, technical file building, clinical trial design and implementation, stability studies, analytical and transport studies, through to approval submissions, provided through Compliance Solutions and IVDeology subsidiaries.
• Companion Diagnostics Development & Manufacturing Integrated development and manufacturing services for companion diagnostics focusing on lateral flow assays, spanning from biomarker validation to FDA approval and commercial launch.
• Performance Evaluation Services Analytical testing and performance evaluation services provided through Abingdon Analytical Ltd to generate required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays.
• Abingdon Simply Test Consumer-facing rapid test brand offering lateral flow products for self-testing, sold through retail, wholesale and distributors globally.
• Pocket Diagnostic Consumer-facing rapid test brand offering lateral flow products for point-of-care testing, distributed through retail and wholesale networks.
• Salistick Saliva-Based Pregnancy Test First rapid saliva-based pregnancy test in the UK and Ireland, marking Abingdon Health's expansion into mainland Europe.
• PCRD Range Off-the-shelf lateral flow solution for researchers to test their molecular lateral flow systems, part of Abingdon Health's product portfolio for the research market.
• LVOne Stroke Triage Test World's first rapid blood test for identifying large vessel occlusion strokes at point of care; developed by UpFront Diagnostics with Abingdon Health as CDMO partner. Measures D-dimer and GFAP biomarkers, delivering results in under 10 minutes from a finger-prick sample.
• DPP3 InvoSelect Companion Diagnostic Lateral flow-based companion diagnostic for invobenitug (procizumab, AK1967) antibody therapy targeting life-threatening cardiogenic and septic shock, co-developed with 4TEEN4 Pharmaceuticals with Abingdon Health as legal manufacturer.

Quantifiable outcome

• More than doubled business in 2025 with similar growth targeted for 2026
• +4 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• VenomAid DiagnosticscoreStrategic or Co-development Partner · 14 May 2026MedTech company developing affordable rapid snakebite diagnostic partnered with Abingdon Health as CDMO partner. Abingdon's accelerated timeline capability enabled rapid prototype production to support clinical studies, including delivery of 200 additional prototypes with few days' notice.
• UpFront DiagnosticscoreStrategic or Co-development Partner · 5 May 2026UpFront Diagnostics launched LVOne, the world's first rapid blood test for identifying large vessel occlusion strokes at point of care, with Abingdon Health serving as CDMO partner handling feasibility through scale-up, quality control, validation, and routine manufacture of dual-biomarker assay.
• 4TEEN4 PharmaceuticalscoreStrategic or Co-development Partner · 30 April 2026German biopharmaceutical company partnered with Abingdon Health to develop DPP3 InvoSelect, a lateral flow-based companion diagnostic for invobenitug (procizumab) antibody therapy targeting life-threatening cardiogenic and septic shock. Abingdon serves as legal manufacturer providing regulatory support, technical expertise, and manufacturing for the CDx which has reached design freeze milestone.
• 52 North (Neutrocheck)secondaryTechnology or Integration · 19 February 202652 North's sepsis test Neutrocheck integrates with Abingdon Health's lateral flow capabilities. The innovative finger-prick blood test simultaneously assesses neutrophil count and CRP levels using microfluidic lateral flow platform technology.
• STRAND Project (Stanford SPARK)secondaryStrategic or Co-development Partner · 5 February 2026Stanford University spin-out partnership with Abingdon Health to develop proof-of-concept for novel molecular diagnostic platform using lateral flow device technology for pathogen detection. Project completed 2.5 weeks ahead of schedule generating critical proof-of-concept data.
• Institut Pasteur Consortium (with FIND, WEHI, AHRI, LSHTM, DiaTropix)coreStrategic or Co-development Partner · 29 January 2026Global consortium led by Institut Pasteur partnered with Abingdon Health to develop multiplexed 4-panel rapid serological diagnostic test for Plasmodium vivax malaria detection. Consortium includes world-leading partners for disease control in remote areas.
• Carus Animal HealthsecondaryStrategic or Co-development Partner · 14 January 2026Veterinary diagnostic company partnered with Abingdon Health for development and manufacturing of point-of-care test for measuring faecal calprotectin in dogs and cats. Shifted from smartphone app to semi-quantitative scorecard performing as effectively as digital reader.
• SymbioTex (Symbio Technologies Ltd)coreTechnology or Integration · 6 November 2025Exclusive partnership with UK-based SymbioTex to supply patented compostable material derived from red seaweed for diagnostic device cassettes. Companies developed working prototype cassettes in standard and mid-stream formats with Abingdon's manufacturing facilities capable of producing over 100 million devices annually using seaweed-based material.

Scale indicators11 records

Recent moves12 records

Expansion highlights7 records

Broad incumbents

• Charles River Laboratories: Leading CRO/CDMO providing preclinical, development, and manufacturing services to pharma and biotech, directly comparable to Abingdon's end-to-end lateral flow CDMO model with overlapping customer base.
• Eurofins Scientific: Global CRO/testing services giant with substantial IVD, lateral flow assay development, and clinical diagnostics testing capabilities serving the same pharma, biotech, and diagnostic customer base as Abingdon Health.
• SGS SA: Major global testing, inspection, and certification company operating extensive life sciences and clinical diagnostics laboratories comparable to Abingdon Analytical's performance evaluation and analytical testing services.
• Catalent (Novo Holdings): Large global CDMO with broad biologic, small molecule, and integrated development-to-manufacturing services, comparable to Abingdon's integrated CDMO positioning though much larger scale.
• bioMérieux SA: Global in vitro diagnostics company with strong lateral flow, immunoassay, and microbiological diagnostics portfolio, comparable to Abingdon's CDMO and consumer diagnostic product positioning across clinical and industrial markets.
• QuidelOrtho Corporation: Major IVD company with leading position in rapid immunoassay and lateral flow diagnostics across clinical and point-of-care markets, directly overlapping Abingdon's CDMO and rapid test product strategy.

Direct peers

• Sekisui Diagnostics: Clinical chemistry, immunoassay, and rapid diagnostic test CDMO and product developer for clinical chemistry and lateral flow, comparable to Abingdon's lateral flow CDMO and OEM product lines.
• OraSure Technologies: Specialist rapid point-of-care diagnostics developer leveraging lateral flow and oral fluid sample collection, with consumer-facing brands comparable to Abingdon Simply Test and Pocket Diagnostic offerings.
• Meridian Bioscience (Revvity): Lateral flow assay development, manufacturing, and life sciences reagents provider serving clinical diagnostics and research markets; the most directly comparable mid-cap peer for Abingdon's lateral flow CDMO and product offering.
• DCN Dx (Diagnostic Consulting Network): Boutique lateral flow assay development and contract manufacturing CDMO serving diagnostics developers, directly comparable as a focused LF CDMO competitor for project-based lateral flow contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Abingdon_Health
• YouTubeyoutube.com/channel/UCZ6lB4QErd1lOgmKJq7lAGw
• LinkedInlinkedin.com/company/abingdon-health

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries9 records

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abingdon Health